<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>INTRODUCTION: Chemotherapy-induced neurotoxicity is a significant source of morbidity for <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> patients </plain></SENT>
<SENT sid="1" pm="."><plain>This study aimed to assess the relationship between preexisting <z:mp ids='MP_0002055'>diabetes</z:mp> and clinically significant (National <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">Cancer</z:e> Institute Common Toxicity Criteria grades 2 and 3) OXIPN; between <z:mp ids='MP_0002055'>diabetes</z:mp>, and the cumulative dose at <z:hpo ids='HP_0003674'>onset</z:hpo> of OXIPN; and between other preexisting medical conditions and the development of OXIPN </plain></SENT>
<SENT sid="2" pm="."><plain>MATERIALS AND METHODS: We reviewed medical records of <z:hpo ids='HP_0000001'>all</z:hpo> patients with stage II-IV <z:hpo ids='HP_0003003'>colon cancer</z:hpo> treated in the <z:e sem="disease" ids="C1387055" disease_type="Disease or Syndrome" abbrv="">Albert</z:e> Einstein <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">Cancer</z:e> Center, Philadelphia, with <z:chebi fb="0" ids="31941">oxaliplatin</z:chebi> from 2005 to 2009 </plain></SENT>
<SENT sid="3" pm="."><plain>Exclusion criteria included preexisting <z:e sem="disease" ids="C0442874" disease_type="Disease or Syndrome" abbrv="">neuropathy</z:e>, previous neurotoxic chemotherapy exposure, and incomplete medical records </plain></SENT>
<SENT sid="4" pm="."><plain>The NCI Common Toxicity Criteria was used to grade <z:hpo ids='HP_0000763'>sensory neuropathy</z:hpo> </plain></SENT>
<SENT sid="5" pm="."><plain>Univariate analysis was used to estimate odds ratios and confidence limits for prevalence of OXIPN in patients with and without <z:mp ids='MP_0002055'>diabetes</z:mp> </plain></SENT>
<SENT sid="6" pm="."><plain>The mean level and cumulative doses were compared using the t test </plain></SENT>
<SENT sid="7" pm="."><plain>RESULTS: Sixty-two patients met the study criteria; 23 oxaliplatin-treated patients were excluded </plain></SENT>
<SENT sid="8" pm="."><plain>The crude incidence of any OXIPN was 65% </plain></SENT>
<SENT sid="9" pm="."><plain>There was no relationship found between development of OXIPN and the presence of <z:mp ids='MP_0002055'>diabetes</z:mp>, smoking, <z:hpo ids='HP_0000822'>hypertension</z:hpo>, or <z:chebi fb="0" ids="35664">statin</z:chebi> use </plain></SENT>
<SENT sid="10" pm="."><plain>However, the mean cumulative dose of <z:chebi fb="0" ids="31941">oxaliplatin</z:chebi> was significantly lower for patients with <z:mp ids='MP_0002055'>diabetes</z:mp> who developed <z:e sem="disease" ids="C0442874" disease_type="Disease or Syndrome" abbrv="">neuropathy</z:e>, compared with those without <z:mp ids='MP_0002055'>diabetes</z:mp> (388 vs. 610 mg/m(2); P = .021) </plain></SENT>
<SENT sid="11" pm="."><plain>CONCLUSION: Although the presence of <z:mp ids='MP_0002055'>diabetes</z:mp> did not appear to affect the severity of OXIPN, patients with <z:mp ids='MP_0002055'>diabetes</z:mp> developed OXIPN at a lower cumulative dose of <z:chebi fb="0" ids="31941">oxaliplatin</z:chebi> (P &lt; .05) </plain></SENT>
<SENT sid="12" pm="."><plain>The results may have implications for treatment of patients with <z:mp ids='MP_0002055'>diabetes</z:mp> and <z:hpo ids='HP_0003003'>colon cancer</z:hpo> </plain></SENT>
</text></document>